🇺🇸 FDA
Patent

US 7129332

Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof

granted A61KA61K2039/505A61K47/6849

Quick answer

US patent 7129332 (Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 31 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K47/6849, A61P, A61P35/00